Kymera Therapeutics, Inc. (NASDAQ:KYMR) Receives Average Recommendation of “Moderate Buy” from Brokerages

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR) have earned an average recommendation of “Moderate Buy” from the twenty-four ratings firms that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, twenty have assigned a buy rating and one has issued a strong buy rating on the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $127.1739.

A number of research firms have issued reports on KYMR. Bank of America boosted their price objective on shares of Kymera Therapeutics from $110.00 to $125.00 and gave the company a “buy” rating in a research report on Tuesday, June 30th. Morgan Stanley reiterated an “overweight” rating and set a $135.00 target price on shares of Kymera Therapeutics in a report on Thursday, August 6th. Guggenheim raised their target price on Kymera Therapeutics from $125.00 to $135.00 and gave the stock a “buy” rating in a research note on Tuesday, July 28th. Oppenheimer restated an “outperform” rating and set a $125.00 price target on shares of Kymera Therapeutics in a report on Wednesday, August 5th. Finally, Truist Financial upped their price target on Kymera Therapeutics from $116.00 to $136.00 and gave the company a “buy” rating in a research report on Monday, June 29th.

Insiders Place Their Bets

In other Kymera Therapeutics news, Director Bruce Booth sold 31,283 shares of the business’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $109.48, for a total value of $3,424,862.84. Following the sale, the director directly owned 461,794 shares of the company’s stock, valued at approximately $50,557,207.12. The trade was a 6.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Bvf Partners L. P/Il sold 1,578,800 shares of the stock in a transaction dated Friday, June 26th. The shares were sold at an average price of $106.50, for a total transaction of $168,142,200.00. Following the sale, the director directly owned 240,123 shares in the company, valued at $25,573,099.50. This trade represents a 86.80% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 3,587,629 shares of company stock valued at $386,183,782 over the last ninety days. 15.98% of the stock is owned by corporate insiders.

Institutional Trading of Kymera Therapeutics

Institutional investors have recently made changes to their positions in the stock. GAMMA Investing LLC raised its holdings in shares of Kymera Therapeutics by 27.5% during the second quarter. GAMMA Investing LLC now owns 454 shares of the company’s stock valued at $52,000 after purchasing an additional 98 shares during the last quarter. Smartleaf Asset Management LLC boosted its stake in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the last quarter. Larson Financial Group LLC boosted its position in Kymera Therapeutics by 81.5% in the third quarter. Larson Financial Group LLC now owns 777 shares of the company’s stock worth $44,000 after purchasing an additional 349 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in Kymera Therapeutics during the fourth quarter valued at approximately $63,000. Finally, Osaic Holdings Inc. grew its position in Kymera Therapeutics by 18,050.0% during the second quarter. Osaic Holdings Inc. now owns 1,089 shares of the company’s stock valued at $48,000 after buying an additional 1,083 shares during the period.

Kymera Therapeutics Stock Performance

NASDAQ:KYMR opened at $120.23 on Friday. The firm has a market cap of $10.00 billion, a PE ratio of -37.11 and a beta of 1.95. Kymera Therapeutics has a fifty-two week low of $39.84 and a fifty-two week high of $130.05. The business has a 50 day moving average price of $112.23 and a 200-day moving average price of $93.44.

Kymera Therapeutics (NASDAQ:KYMR) last issued its earnings results on Wednesday, August 5th. The company reported ($0.62) EPS for the quarter, topping the consensus estimate of ($0.71) by $0.09. Kymera Therapeutics had a negative net margin of 285.33% and a negative return on equity of 21.22%. The company had revenue of $65.00 million for the quarter, compared to the consensus estimate of $32.78 million. During the same period in the previous year, the firm earned ($0.95) earnings per share. The firm’s revenue for the quarter was up 465.2% on a year-over-year basis. Research analysts predict that Kymera Therapeutics will post -3.78 EPS for the current year.

About Kymera Therapeutics

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.